NASDAQ · Biotechnology

CELZ (CELZ) Stock

$0.79 -2.09% NASDAQ: CELZ Healthcare

Valuation

MetricValue
Price$0.79
Market Cap$2.05M
P/E Ratio-1.47
P/B Ratio1.34
P/S Ratio1849.47
EPS (TTM)$-1.43
52-Week High$6.25
52-Week Low$0.79
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-81.17%
ROA-50.22%
ROCE-75.00%
Gross Margin-39.87%
Operating Margin-1980.50%
Net Margin-1920.66%
Debt/Equity0.00
Current Ratio19.69

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-3.0M$-10.0M$-6.0M$-6.0M$-6.0M
Net Profit$19.0M$-10.0M$-5.0M$-5.0M$-6.0M
EPS$56.10$-9.28$-3.76$-3.71$-2.52
Op Margin-3562.2%-11562.5%-62445.9%-52216.9%-102380.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$11.0M$19.0M$11.0M$7.0M$8.0M
Total Liabilities$1.0M$3.0M$0$0$0
Cash$11.0M$8.0M$3.0M$6.0M$7.0M
Borrowings$0$0$0$0$0

Latest News

Creative Medical Technology Holdings Issues Mid-Year Update GlobeNewswire · Jul 1, 2026 Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds GlobeNewswire · Jun 30, 2026 These Three Stocks Fell More Than 10% Today To Hit 52-Week Lows -- What's Driving The Investor Skepticism? Stocktwits · Jun 26, 2026 Top Premarket Decliners MT Newswires · Jun 26, 2026 Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain GlobeNewswire · Jun 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-8.0M$-8.0M$-5.0M$-6.0M
Investing Cash Flow$0$-10.0M$3.0M$6.0M$0
Financing Cash Flow$-1.0M$0$0$0$0
Net Cash Flow$11.0M$-2.0M$-5.0M$2.0M$1.0M
Free Cash Flow$-2.0M$-8.0M$-8.0M$-5.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-0.38
FCF Yield-100.72%
Quick Ratio19.69
Interest Coverage—
Return 1Y-67.25%
Return 3Y-83.29%
Return 5Y-99.48%

Ownership

Insiders Held0.74%
Institutions Held5.07%
Institutions Float Held5.10%
Institutional HolderSharesReport Date
Geode Capital Management, LLC38,2902026-03-31
Vanguard Capital Management LLC20,3502026-03-31
Xtx Topco Ltd14,2602026-03-31
Susquehanna International Group, LLP10,4692026-03-31
Global Retirement Partners, LLC7,9182025-12-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACXP $1.40 -1.40% -0.36 $2.22M 0.00%
ADIL $3.33 +1.22% -1.14 $3.20M 0.00%
ADXNAddex Therapeutics Ltd $5.89 -0.17% -0.72 $4.24M 0.00%
ALZN $1.35 +0.75% -0.11 $5.14M 0.00%
APRE $0.62 -1.16% -0.47 $4.06M 0.00%

About CELZ

CELZ is led by CEO Timothy Warbington, employs 4 people, headquartered in US, publicly traded since 2015.

CELZ stock trades at $0.79 with a market capitalization of $2.05M. The stock is valued at a price-to-earnings (P/E) ratio of -1.47, price-to-book of 1.34, price-to-sales of 1849.47. Over the past 52 weeks the stock has ranged between $0.79 and $6.25, and currently trades 87.4% below its 52-week high.

On profitability, CELZ generates a return on equity (ROE) of -81.17%, return on capital employed of -75.00%, an operating margin of -1980.50%, a net profit margin of -1920.66%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides